Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Think zinc: Another metal that can transform the energy storage sector

By Ron MacDonald, President and CEO of Zinc8 Energy Solutions Inc. Mines worldwide extract more than 11.9 million metric tons of zinc annually. There are zinc mines in over 50 countries around the world, and while the metal plays a key role in the steel industry, few ...
Rockstone Research | June 29, 2020 |

PCR Testing: XPhyto Disrupts a Blockbuster Business

It’s the technological evolution that could transform the US $84.4 billion Covid-19 diagnostics market. Vancouver-based life sciences company XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) expects its rapid Covid-19 test system to be approv...
Marc Davis | February 25, 2021 |

Invitae Corp. Enters into Definitive Agreement to Acquire ArcherDX

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today...
Streetwise Reports | June 23, 2020 |

This Is What First Lagarde’s Speech Means for Gold

Overbought and oversold Learning to master the markets is like drinking from a fire hose. This does not change, no matter at what stage of the game you are. The vastness of possibilities and the challenges of psychology are endless. Therefore the only way of mane...
Korbinian Koller | December 6, 2019 |

New Century Resources, Alcidion Group, Telix Pharmaceutical, Marley Spoon - emerging ASX companies

The Australian stock exchange, which is based in Sydney, has been called the Australian Securities Exchange (ASX) since 2006. Since 1987, the trading place for securities has been located at this central location. Previously, the business with investments in various cities was...
Mario Hose | May 27, 2020 |

Buzz on the Bullboards: The ups and downs of the fall investing season

For us here on the West Coast it has been a hot autumn and the markets have been just as intense. This means Bullboard activity has also been sizzling. Many sectors have seen new (and returning) companies generate a lot of discussion as a result. This week we&CloseCur...
Jonathon Brown | October 13, 2022 |

Q&A with Cerro de Pasco Resources: Newly appointed CTO on the value of sustainable mining

If the World Economic Forum is any authority on the subject, the mining and metals sector – in its inherent connection to almost all industry value chains – “is an integral part of any foreseeable economy and society.” To that end, and with an ever-growi...
Oliver Gray | July 9, 2020 |

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. Yesterday afternoon, The Woodlands, Tex.-based Lexicon Pharmaceu...
Streetwise Reports | September 12, 2019 |

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
Streetwise Reports | September 25, 2019 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |
1 2 3 4 5 6